Late-Stage Pipeline Monitor
Selected Phase 3, registration-stage and recent pivotal programs — Pfizer · Merck · Johnson & Johnson · EyePoint · Ionis
Data reviewed:
September 5, 2026
September 5, 2026
How to read this: The purpose tag beside every formal drug name gives the plain-language therapeutic area. Click any row for the latest program note and an official source.
Scope: This is a selected late-stage monitor, not an exhaustive company pipeline or investment recommendation. Programs and timelines can change; verify the linked company source before making decisions. EyePoint currently has one lead Phase 3 asset represented across two pivotal trials.